The current study focuses on unresectable stage III non-small cell lung cancer (NSCLC)
patients who have disease progression while on Durvalumab consolidation after concurrent
chemoradiation with a goal of cure. The overall hypothesis of this study is that the addition
of Copanlisib to Durvalumab will be well-tolerated at a biweekly schedule. It will test
whether the addition of Copanlisib to Durvalumab can overcome resistance to Durvalumab.